"This model, and the projected cost savings with Andexxa compared to 4F-PCC outlined in our study, is important to share among hospital pharmacists and administrators," said Mr. ![]() The data was presented by John Fanikos, B.Pharm., M.B.A., executive director of pharmacy services at Brigham and Women's Hospital, Boston, in a poster session at the Emergencies in Medicine Meeting, which is taking place March 1-6 in Park City, Utah. ![]() SOUTH SAN FRANCISCO, Calif., Ma/PRNewswire/ - Portola Pharmaceuticals, Inc.(®) (Nasdaq: PTLA) today announced the presentation of new data demonstrating that using Andexxa(®) to treat patients with intracranial hemorrhage (ICH) associated with the oral Factor Xa inhibitors apixaban or rivaroxaban is projected to provide a net reduction in costs to an acute care hospital.
0 Comments
Leave a Reply. |